1. P1126: MOSUNETUZUMAB IS EFFICACIOUS AND WELL TOLERATED IN PATIENTS AGED <65 AND ≥65 YEARS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND ≥2 PRIOR THERAPIES: SUBGROUP ANALYSIS OF A PIVOTAL PHASE II STUDY. (23rd June 2022) Authors: Matasar, M.; Bartlett, N. L.; Sehn, L. H.; Schuster, S. J.; Assouline, S.; Giri, P.; Kuruvilla, J.; Canales, M.; Dietrich, S.; Fay, K.; Ku, M.; Nastoupil, L. J.; Wei, M. C.; Yin, S.; To, I.; Turner, D.; Huang, H.; Min, J.; Penuel, E.; Budde, L. E. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1016 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗